Clinical Trials Logo

Metastatic Neoplasm clinical trials

View clinical trials related to Metastatic Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05617716 Recruiting - Metastatic Neoplasm Clinical Trials

Spine Radiosurgery for Symptomatic Metastatic Neoplasms

Start date: January 25, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.

NCT ID: NCT05103358 Recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT02560311 Recruiting - Breast Cancer Clinical Trials

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

Start date: December 2014
Phase: N/A
Study type: Observational

The aim of this study is to analyze cases of human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) of the last 10 years at the University Hospital of Zurich to assess the efficacy of the treatment with trastuzumab in HER2-positive MBC and to find out associations between different variables and the outcome. The aim is to find out probable prognostic factors and patterns of disease progression. Prognostic factors could optimize treatment approaches and result in a delay of disease progression.